Pfizer Inc. (NYSE:PFE) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its holdings in Pfizer Inc. (NYSE:PFE) by 2.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 74,352 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Pfizer were worth $2,013,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the 3rd quarter worth $30,000. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the 3rd quarter worth $34,000. VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the 4th quarter worth $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.0 %

Shares of PFE traded up $0.01 on Tuesday, hitting $26.27. 11,960,345 shares of the stock traded hands, compared to its average volume of 41,945,789. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $148.75 billion, a P/E ratio of 73.28, a P/E/G ratio of 1.17 and a beta of 0.61. The stock’s 50 day moving average is $27.08 and its two-hundred day moving average is $28.56. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.